Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

ReShape Lifesciences Inc. RSLS NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
34/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

ReShape Lifesciences Inc. (RSLS) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 1 Buy, 2 Hold.

RSLS Analyst Ratings

Hold
3
Ratings
1 Buy
2 Hold
Based on 3 analysts giving stock ratings to ReShape Lifesciences Inc. in the past 3 months
Rating breakdown
Buy
1 33%
Hold
2 67%
33%
Buy
1 analysts
67%
Hold
2 analysts
0%
Sell
0 analysts

People Also View

OPGN
OPGN
OpGen, Inc.
$23.91
+64.36%
 HSDT
HSDT
Helius Medical Technologies, Inc.
$1.98
-2.46%
 IINN
IINN
Inspira Technologies Oxy B.H.N. Ltd.
$0.48
-6.50%
 NURO
NURO
NeuroMetrix, Inc.
$4.58
+5.05%
 SINT
SINT
Sintx Technologies, Inc.
$2.80
-2.44%
 TNON
TNON
Tenon Medical, Inc.
$0.81
-1.28%
 TLIS
TLIS
Talis Biomedical Corporation
$2.84
+0.00%
 HSCS
HSCS
Heart Test Laboratories, Inc.
$1.97
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message